Who
Gene Mack
CEO, President
Company insider
Files Form 4 as: CEO, President, Gain Therapeutics; CFO and Treasurer, SELLAS Life Sciences Group.
In numbers
- Trades disclosed
- 7
- Buys
- 1
- Sells
- 0
- Bought
- $15K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 20 Apr 2018
- Last trade
- 24 Mar 2026
- Last filed
- 26 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Mar 2026filed 26 Mar 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 24 Mar 2026filed 26 Mar 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 20 Mar 2025filed 21 Mar 2025 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 6 Jan 2025filed 7 Jan 2025 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —271,325 at $0.00 | filing |
| 9 Aug 2024filed 12 Aug 2024 | GANX Gain TherapeuticsBiotechnology | SEC FORM 4 Bought | $15K14,400 at $1.01 | filing |
| 8 Apr 2024filed 8 Apr 2024 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 20 Apr 2018filed 24 Apr 2018 | SLS SELLAS Life Sciences Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
Gene Mack International, Inc. Earns CTPAT Certification as Trade Rules Tightenmanilatimes.net · 29 Sep 2026
1 headline in the last 90 days name Gene Mack; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.